ClinicalTrials.gg
Not yet recruitingNCT07698080Updated Jul 14, 2026

Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploidentical Hematopoietic Stem Cell Transplantation

A Phase 2 interventional study of Intravenous Immunoglobulin and Dexamethasone in Leukemia, Lymphoma and Thalassemia, sponsored by Hematology department of the 920th hospital. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Hematology department of the 920th hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 38 studies testing dexamethasone in Leukemia — 5 open to participants now, 7 under way, 1 of them phase 3. Dexamethasone · Leukemia.

Planned enrollment
18th of 37
60 · median 59
Started
2026
the only one that year
Phase 2
19 of 38
1 open now
Registered
38th of 38
by date

Among the 38 studies testing dexamethasone in Leukemia, this one is the 18th largest by planned enrollment of the 37 interventional ones that give a count, is the only one that started in 2026, is one of 19 in phase 2, and was the 38th registered.

Leukemia

2,382 studies on the registry are indexed under Leukemia; 252 are open to participants now.

Browse Leukemia studies →

Open to participants now

5 of the 38 studies testing dexamethasone in Leukemia are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 206 Leukemia studies recruiting now, 111 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 85 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing dexamethasone in Leukemia, or all of them as a file.
02

Study summary

This study tests whether a combination of three treatments - dexamethasone (a steroid), intravenous immunoglobulin (IVIG, a protein that helps the immune system), and an extra dose of donor mononuclear cells - can safely lower harmful antibodies called donor-specific antibodies (DSA) in patients who need a stem cell transplant from a half-matched (haploidentical) family donor.

In these transplants, DSA are antibodies made by the patient's own body that attack the donor's stem cells. If DSA levels are high, the transplant is more likely to fail - the donor cells may not "take" (engraft). Currently, there is no single, simple, and reliable way to reduce DSA, and many existing methods have drawbacks.

Based on the investigators' earlier experience in 11 patients, this three-part approach seemed to work well. All patients successfully engrafted, and DSA levels dropped quickly. Now the study team want to confirm these results in a larger, prospective, multicenter study.

The investigators plan to enroll 60 patients aged 18-65 with blood cancers or other blood disorders who need a haploidentical transplant, have DSA levels above 500 MFI (a measure of antibody strength), and have no other suitable donor available. Participants will receive:

  • Dexamethasone (25 mg/m²) for 4 days before transplant,
  • IVIG (1 g/kg) one day before transplant,
  • Extra mononuclear cells on transplant day - the extra amount depends on how high their DSA level is (low, medium, or high).

The main goal is to see how many patients have primary graft failure (when the donor cells never engraft). The study team will also measure how long it takes for blood counts to recover, rates of graft-versus-host disease, survival, and side effects. All participants will be followed for 1 year.

This study will help the investigators find out whether this combination is a safe, simple, and effective way to improve transplant success for patients with DSA who have no other donor options.

03

Conditions studied

  • Leukemia
  • Lymphoma
  • Thalassemia
  • Aplastic Anemia
  • Myelodysplastic Syndromes
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of benign or malignant hematological diseases (including leukemia, lymphoma, thalassemia, aplastic anemia, myelodysplastic syndromes, etc.) confirmed by NCCN guidelines, and determined by the investigator to require hematopoietic stem cell transplantation.
  2. (ECOG) performance status ≤ 3.
  3. Donor-specific antibody (DSA) mean fluorescence intensity (MFI) > 500.
  4. Age between 18 and 65 years (age limits are also captured separately in the eligibility module).
  5. Body weight between 40 kg and 100 kg.
  6. No other suitable donor available (i.e., no DSA-negative related donor or unrelated donor).

Exclusion criteria

Exclusion Criteria:

  1. Patients unsuitable for transplantation or without willingness to undergo transplantation, or diagnosed with non-hematological diseases.
  2. Estimated \< 1 month.
  3. Known allergy to any drug or intervention used in the study regimen.
  4. Pregnancy, lactation, active severe infection, or severe major organ dysfunction.
  5. Severe psychiatric or neurological disorders that may affect the ability to provide and/or to report adverse events or comply with observation.
  6. Refusal or inability to sign the informed consent form.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Triple Therapy to Reduce DSA in Haploidentical HSCT: A Prospective Multicenter Study

    Participants receive dexamethasone (25 mg/m² × 4 days) and intravenous immunoglobulin (1 g/kg) prior to haploidentical hematopoietic stem cell transplantation, plus an additional dose of donor mononuclear cells on transplant day. The additional dose is stratified by baseline DSA MFI level: ≤5000: +2±2×10⁸/kg; 5000-10000: +4±2×10⁸/kg; \>10000: +6±2×10⁸/kg.

    Biological: Intravenous Immunoglobulin · Drug: Dexamethasone · Biological: Mononuclear Cells

Interventions

  • BiologicalImmunoglobulins, IntravenousStudies of Immunoglobulins, IntravenousImmunoglobulins, Intravenous pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1 g/kg intravenously on day -1 prior to transplant.

  • 25 mg/m² intravenously for 4 days prior to transplant (days -4 to -1).

  • BiologicalMononuclear Cells

    Additional donor MNCs infused on day 0. Dose stratified by baseline DSA MFI level: ≤5000: +2±2×10⁸/kg; 5000-10000: +4±2×10⁸/kg; \>10000: +6±2×10⁸/kg.

06

What researchers measure

Primary outcomes

  1. Primary Graft Failure (PGF)

    Time frame: Day +28 post-transplant

Secondary outcomes

  1. Neutrophil and Platelet Engraftment Time

    Time frame: Up to 28 days post-transplant

  2. Dynamic Changes in Donor-Specific Antibody (DSA) MFI Levels

    Time frame: Pre-transplant (day -14 to -1) through day +22 post-transplant

  3. Incidence of Acute and Chronic Graft-Versus-Host Disease

    Cumulative incidence of acute GVHD (aGVHD) graded by standard criteria within 100 days post-transplant, and chronic GVHD (cGVHD) graded by NIH consensus criteria from day +100 through 1 year post-transplant.

    Time frame: Up to 1 year post-transplant

  4. Overall Survival and Disease-Free Survival

    Overall survival (OS) defined as time from transplant to death from any cause. Disease-free survival (DFS) defined as time from transplant to relapse, progression, or death from any cause. Estimated using Kaplan-Meier method at 1 year.

    Time frame: Up to 1 year post-transplant

  5. Incidence of Adverse Events

    Incidence of infectious complications (bacterial, viral, fungal), bleeding events, and other treatment-emergent adverse events. Graded according to CTCAE criteria.

    Time frame: Up to 1 year post-transplant

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jul 2028, 24 months later.

Of 144 non-industry phase 2 interventional studies under Leukemia, half reached primary completion within 92 months of starting (the median), counting those still running; a quarter within 60 and three quarters within 129. This study's planned 24 months is below that.

Counting every sponsor, half of 176 studies reached it within 76 months; a quarter within 44 and three quarters within 123.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 13, 2026
StartEst.
Jul 3, 2026
Primary completionEst.
Jul 3, 2028
CompletionEst.
Jul 3, 2028
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07698080
Lead sponsor
Hematology department of the 920th hospital
Responsible party
Sponsor
First posted
Jul 13, 2026
Start date
Jul 3, 2026 (estimated)
Primary completion
Jul 3, 2028 (estimated)
Completion
Jul 3, 2028 (estimated)
Last update
Jul 14, 2026

Study contacts

Sanbin Wang
Contact
sanbin1011@163.com
+8613187424131
Xi Xiong
Contact
15987422538@163.com
+8615987422538

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Immunoglobulins, Intravenous · Dexamethasone

Start the discussion